Skip to main content
. 2016 Aug 12;7(37):60593–60608. doi: 10.18632/oncotarget.11260

Figure 3. Kaplan-Meier analysis with a log-rank test of survival.

Figure 3

Disease-free survival a. and overall survival b. were significantly shorter in patients with Barx2-negative tumors than in those with Barx2-positive tumors (*** P< 0.001 for both, log-rank test). Comparisons of overall survival between patients with Barx2-negative tumors and those with Barx2-positive tumors in early UICC stage (I-II) cohort and in advanced UICC stage (III-IV) cohort c-d. and in patients with or without relapse e-f. P-values were calculated by log-rank test and P<0.05 was considered significant.